# A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

> **NCT07294300** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 124 (estimated)

## Conditions studied

- Relapsed/Refractory Hematological Malignancies

## Interventions

- **DRUG:** QLS2313

## Key facts

- **NCT ID:** NCT07294300
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294300, "A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT07294300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*